The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Open accessAbstract
Background Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumour expression of PD-L1.Methods ATLANTIC is a phase 2, open-label, single-arm trial at 139 study centres in Asia, Europe, and North America. Eligible patients had advanced NSCLC with disease progression following at least two previous systemic regimens, including platinum-based chemotherapy (and tyrosine kinase inhibitor therapy if indicated); were aged 18 years or older; had a WHO performance status score of 0 or 1; and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key exclusion criteria included mixed small-cell lung cancer and NSCLC histology; previous exposure to any anti-PD-1 or anti-PD-L1 antibody; and any previous grade 3 or worse immune-related adverse event while receiving any immunotherapy agent. Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression. Patients in cohorts 2 and 3 had EGFR-/ALK- NSCLC; cohort 2 included patients with at least 25%, or less than 25%, of tumour cells with PD-L1 expression, and cohort 3 included patients with at least 90% of tumour cells with PD-L1 expression. Patients received durvalumab (10 mg/kg) every 2 weeks, via intravenous infusion, for up to 12 months. Retreatment was allowed for patients who benefited but then progressed after completing 12 months. The primary endpoint was the proportion of patients with increased tumour expression of PD-L1 (defined as ≥25% of tumour cells in cohorts 1 and 2, and ≥90% of tumour cells in cohort 3) who achieved an objective response, assessed in patients who were evaluable for response per independent central review according to RECIST version 1.1. Safety was assessed in all patients who received at least one dose of durvalumab and for whom any post-dose data were available. The trial is ongoing, but is no longer open to accrual, and is registered with ClinicalTrials.gov, number NCT02087423.Findings Between Feb 25, 2014, and Dec 28, 2015, 444 patients were enrolled and received durvalumab: 111 in cohort 1, 265 in cohort 2, and 68 in cohort 3. Among patients with at least 25% of tumour cells expressing PD-L1 who were evaluable for objective response per independent central review, an objective response was achieved in 9 (12·2%, 95% CI 5·7-21·8) of 74 patients in cohort 1 and 24 (16·4%, 10·8-23·5) of 146 patients in cohort 2. In cohort 3, 21 (30·9%, 20·2-43·3) of 68 patients achieved an objective response. Grade 3 or 4 treatment-related adverse events occurred in 40 (9%) of 444 patients overall: six (5%) of 111 patients in cohort 1, 22 (8%) of 265 in cohort 2, and 12 (18%) of 68 in cohort 3. The most common treatment-related grade 3 or 4 adverse events were pneumonitis (four patients [1%]), elevated gamma-glutamyltransferase (four [1%]), diarrhoea (three [1%]), infusion-related reaction (three [1%]), elevated aspartate aminotransferase (two [<1%]), elevated transaminases (two [<1%]), vomiting (two [<1%]), and fatigue (two [<1%]). Treatment-related serious adverse events occurred in 27 (6%) of 444 patients overall: five (5%) of 111 patients in cohort 1, 14 (5%) of 265 in cohort 2, and eight (12%) of 68 in cohort 3. The most common serious adverse events overall were pneumonitis (five patients [1%]), fatigue (three [1%]), and infusion-related reaction (three [1%]). Immune-mediated events were manageable with standard treatment guidelines.Interpretation In patients with advanced and heavily pretreated NSCLC, the clinical activity and safety profile of durvalumab was consistent with that of other anti-PD-1 and anti-PD-L1 agents. Responses were recorded in all cohorts; the proportion of patients with EGFR-/ALK- NSCLC (cohorts 2 and 3) achieving a response was higher than the proportion with EGFR+/ALK+ NSCLC (cohort 1) achieving a response. The clinical activity of durvalumab in patients with EGFR+ NSCLC with ≥25% of tumour cells expressing PD-L1 was encouraging, and further investigation of durvalumab in patients with EGFR+/ALK+ NSCLC is warranted.Funding AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to EGFR-mutation, ALK rearrangement is also related to the poor response to α-PD-1/PD-L1 [199].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,782
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationRizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Self-citation
Cited by
Sorted by citations
Items 301–400 of 570
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
Tonk, E. H. J., van Lindert, A. S. R., Verhoeff, J. J. C., & Suijkerbuijk, K. P. M. (2019) · Case Reports in Oncology · doi:10.1159/000502202 · Cited by 12
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer
Somasundaram, A., Socinski, M. A., & Villaruz, L. (2020) · Drugs · doi:10.1007/s40265-020-01320-0 · Cited by 12
Zhang, C., & Wang, H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.020 · Cited by 12
Chen, Q., Shang, X., Liu, G., Ma, X., Han, W., Wang, X., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931718 · Cited by 12
Dammak, S., Cecchini, M. J., Breadner, D. A., & Ward, A. D. (2023) · Journal of medical imaging · doi:10.1117/1.jmi.10.1.017502 · Cited by 12
Михайлович, П. В., Таширева, Л. А., Savelieva, O. E., Denisov, E. V., Кайгородова, Е. В., Zavyalova, M. V., & Чердынцева, Н. В. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s175161 · Cited by 12
Parrondo, R. D., & Sher, T. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s192490 · Cited by 12
Stimulatory and Inhibitory Co-signals in Autoimmunity
Okazaki, T., & Okazaki, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_8 · Cited by 12
Liu, C., Xu, B., Li, Q., Li, A., Li, L., Yue, J., Hu, Q., & Yu, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0899-6 · Cited by 13
Wu, Y., Li, D., Wu, M., Yang, Y., Shen, M., & Chen, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004663 · Cited by 11
Cheng, Y., Zhou, Q., Han, B., Fan, Y., Li, S., Chang, J., Sun, S., Fang, J., Chen, Y., Sun, J., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.013 · Cited by 11
Self-citationLi, S., Yuan, T., Yuan, J., Zhu, B., & Chen, D. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06030-8 · Cited by 13
Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma
Wills, S., Hochmuth, L. K., Bauer, K. S., & Deshmukh, R. R. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.08.010 · Cited by 11
Prelaj, A., Proto, C., Russo, G. L., Signorelli, D., Ferrara, R., Mensah, M., Galli, G., Toma, A. D., Viscardi, G., Brambilla, M., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-231 · Cited by 11
Self-citationEvaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
Pisapia, P., Iaccarino, A., Luca, C. D., Acanfora, G., Bellevicine, C., Bianco, R., Daniele, B., Ciampi, L., Felice, M. D., Fabozzi, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158541 · Cited by 11
Yang, F., Wang, Y., Tang, L., Mansfield, A. S., Adjei, A. A., Leventakos, K., Duma, N., Wei, J., Wang, L., Liu, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.955440 · Cited by 12
Ding, J., Ding, X., & Leng, Z. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2170879 · Cited by 11
A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy
McCoach, C. E. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.009 · Cited by 11
Jessup, J. M., Kabbout, M., Korokhov, N., Joun, A., Tollefson, A. E., Wold, W. S. M., & Mattoo, A. R. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665960 · Cited by 11
Borghaei, H., Redman, M. W., Kelly, K. L., Waqar, S., Robert, F., Kiefer, G. J., Stella, P. J., Minichiello, K., Gandara, D. R., Herbst, R. S., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.015 · Cited by 11
Cheng, Y., Yang, B., Ouyang, W., Chen, J., Zhang, W., Chen, G., Zhang, J., Yu, J., & Xie, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920047 · Cited by 11
Yang, H., Wang, H., Zhou, X., & Zhang, X. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.01.001 · Cited by 11
Ferro, A., Filoni, A., Pavan, A., Pasello, G., Guarneri, V., Conte, P., Alaibac, M., & Bonanno, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.570921 · Cited by 10
van Duijvenvoorde, M., Sarah Derks, A., Bahce, I., Leemans, C. R., van de Ven, R., & Fransen, M. F. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1363 · Cited by 10
Wang, Z., Zhou, F., Xu, S., Wang, K., & Ding, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6453 · Cited by 9
Ramos-Ramírez, M., Caballé‐Perez, E., Lucio-Lozada, J., Romero-Núñez, E., Castillo-Ruiz, C., Dorantes-Sánchez, L., Flores‐Estrada, D., Recondo, G., Barrios‐Bernal, P., Cabrera-Miranda, L. A., et al. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10245-7 · Cited by 12
Liu, S., Zhou, F., Liu, Z., Xiong, A., Jia, Y., Zhao, S., Zhao, C., Li, X., Jiang, T., Han, R., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-396 · Cited by 10
Mortezaee, K., & Majidpoor, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14566 · Cited by 11
Biomarkers of immunotherapy for non-small cell lung cancer
Shirasawa, M., Yoshida, T., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad134 · Cited by 10
Li, H., Wu, C., Chang, W., Zhong, L., Gao, W., Zeng, M., Wen, Z., Mai, S., & Chen, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810243 · Cited by 10
Self-citationThe 150 most important questions in cancer research and clinical oncology series: questions 94–101
Communications, C. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0341-9 · Cited by 10
Zhang, Y., Zhao, M., Cao, S., Zhang, X., & Du, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13569 · Cited by 10
Immunotherapy in oncogene addicted non-small cell lung cancer
McLean, L. S., Leal, J. L., Solomon, B., & John, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-772 · Cited by 11
Xia, L., Yu, Y., Lan, F., Yan, J., Li, J., Li, W., & Xia, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760703 · Cited by 10
Downregulation of PD‐L1 and HLA‐I in non‐small cell lung cancer with ALK fusion
Mu, D., Guo, J., Yu, W., Zhang, J., Ren, X., & Han, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14372 · Cited by 10
First case of cutaneous sarcoidosis within tattoos under durvalumab
Rousseau, P., Raimbourg, J., Robert, M., Dansette, D., Dréno, B., Peuvrel, L., & Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments (2019) · International Journal of Dermatology · doi:10.1111/ijd.14484 · Cited by 10
Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
Li, C., & Song, Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001610 · Cited by 10
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
Arnaoutakis, K., Wan, Y., Elliott, J., Young, M., Yin, Y., Leventakos, K., Lin, H. M., & Dimou, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02899-6 · Cited by 9
Morgan, C., Kurland, J. F., Patel, M., O’Brien, C., Concepcion, P., Doherty, G. J., Hois, S., Negro, A., Pavlović, D., & Robbins, K. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011140 · Cited by 9
Maio, M., Lahn, M., Giacomo, A. M. D., Covre, A., Calabrò, L., Ibrahim, R. A., Fox, B. A., Tank, T. S. T., Abrignani, S., Allavena, P., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02023-4 · Cited by 10
Prognostic value of Peripheral Naive CD8 + T Cells in Oligometastatic Non-Small-Cell Lung Cancer
Zhao, X., Zhang, Y., Gao, Z., & Han, Y. (2021) · Future Oncology · doi:10.2217/fon-2021-0728 · Cited by 9
Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives
Ryser, C. O., Diebold, J., & Gautschi, O. P. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000494 · Cited by 9
The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
Pistamaltzian, N. F., Georgoulias, V., & Kotsakis, A. P. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1593828 · Cited by 9
Anaplastic lymphoma kinase-special immunity and immunotherapy
Guo, Y., Guo, H., Zhang, Y., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908894 · Cited by 10
Zhu, L., Yu, X., Tang, X., Hu, C., Wu, L., Liu, Y., & Zhou, Q. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002981 · Cited by 8
Wang, X., Meng, X., Cai, G., Jin, P., Bai, M., Fu, Y., Wang, Z., Guo, J., & Xiao, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111684 · Cited by 8
Yang, M., Cao, H., Wang, C., Yu, C., & Sun, P. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1031_23 · Cited by 9
Chen, Y.-C., Chen, A., Hong, R., Huang, B. E., & Pirooznia, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-82903-9 · Cited by 9
Self-citationBjørnhart, B., Hansen, K. H., Jørgensen, T. L., Herrstedt, J., & Schytte, T. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100056 · Cited by 8
Li, F., Liao, B.-C., Wang, T., Qi, T., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918709 · Cited by 8
Chen, J., Zheng, Q., Zhu, S., Qiu, D., & Wang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54557-0 · Cited by 8
Yamaguchi, T., Shimizu, J., Matsuzawa, R., Watanabe, N., Horio, Y., & Fujiwara, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12554-6 · Cited by 8
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer
Li, C., Shi, M., Lin, X., Zhang, Y., Yu, S., Zhou, C., Yang, N., Zhang, J., Zhang, F., Lv, T., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-832 · Cited by 8
Hita-Millan, J., Carracedo, Á., & Fernández–Rozadilla, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100971 · Cited by 8
Li, Y., Chen, Z., Tao, W., Sun, N., & He, J. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02868-w · Cited by 8
Zhou, H., Lin, L., Qin, T., Ren, W., Tan, Y., Yang, Q., Xu, H., Xie, X., Chen, Y., Liu, S., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1022 · Cited by 7
Self-citationShirasawa, M., Yoshida, T., Matsutani, T., Takeyasu, Y., Goto, N., Yagishita, S., Kitano, S., Kuroda, H., Hida, T., Kurata, T., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00781-w · Cited by 7
Ying, K., Zou, L., Wang, D., Wang, R., & Qian, J. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073246841230922052004 · Cited by 7
Kim, D. H., Lim, S. T., Kim, H. R., Kang, E. J., Ahn, H. K., Lee, Y., Sun, D. S., Kwon, J. H., Lee, S., Lee, H. W., et al. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106739 · Cited by 7
Self-citationImmune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?
Lee, J., & Ahn, M. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000698 · Cited by 6
Self-citationPark, J. H., You, G. L., Ahn, M., Kim, S.-W., Hong, M. H., Han, J., Ock, C.-Y., Lee, J.-S., Oh, I., Lee, S. Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03527-4 · Cited by 7
Self-citationImmune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II
Bukamur, H. S., Alkrekshi, A., Katz, H., Alsharedi, M. F., Shweihat, Y., & Munn, N. J. (2021) · Southern Medical Journal · doi:10.14423/smj.0000000000001295 · Cited by 8
Zhao, J., Feng, Y., & Liu, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27832 · Cited by 7
Liang, S., Wang, H., Zhang, Y., Tian, H., Li, C., & Hua, D. (2024) · Cancer Medicine · doi:10.1002/cam4.7208 · Cited by 7
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
Früh, M., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz185 · Cited by 7
Yu, H., Sun, S., Hu, X., Xia, J., Wang, J., & Chen, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s185115 · Cited by 7
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
Shibata, Y., & Murakami, S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1764936 · Cited by 7
Self-citationOgawa, K., Kaneda, H., Kawamoto, T., Tani, Y., Izumi, M., Matsumoto, Y., Sawa, K., Suzumura, T., Watanabe, T., Mitsuoka, S., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00947-w · Cited by 7
Li, J., Yan, J., Cao, R., Du, G., & Zhao, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575739 · Cited by 7
Joshi, K., Muhith, A., Obeid, M., Milner-Watts, C., Yousaf, N., Popat, S., Davidson, M., Bhosle, J., O'Brien, M. E. R., & Minchom, A. R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.04.021 · Cited by 7
A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
Cheong, E., & Ho, G. F. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101478 · Cited by 7
Neumann, M., Murphy, N. J., & Seetharamu, N. (2022) · PubMed · Cited by 7
Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets
SHAM, N., Zhao, L., ZHU, Z., ROY, T. M., XIAO, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2022) · Anticancer Research · doi:10.21873/anticanres.15816 · Cited by 8
Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7
Li, J., Lu, S., Tian, Y., Jiang, L., Li, L., Xie, S.-H., & Li, Q. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110316 · Cited by 6
Immunotherapy in EGFR-mutant non-small cell lung cancer
Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7
Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yue, D., Huang, M., Song, P., Chen, Y., Li, B., Fu, J., Guo, J., Cheng, C., Chen, Q., Xu, S., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2518990 · Cited by 7
Self-citationZhou, J., Chu, X., Zhao, J., Xie, M., Wu, J., Yu, X., Fang, Y., Li, Y., Li, X., & Su, C. (2023) · Biological Procedures Online · doi:10.1186/s12575-023-00215-0 · Cited by 6
Kuribayashi, T., Ohashi, K., Nishii, K., Ninomiya, K., Tsubata, Y., Ishikawa, N., Kodani, M., Kanaji, N., Yamasaki, M., Fujitaka, K., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05618-4 · Cited by 6
Goldschmidt, J. H., Annavarapu, S., Venkatasetty, D., Wang, Y., Santorelli, M. L., Burke, T. W., & Pennell, N. A. (2024) · Immunotherapy · doi:10.2217/imt-2023-0313 · Cited by 6
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.006 · Cited by 6
Sposito, M., Eccher, S., Pasqualin, L., Scaglione, I. M., Avancini, A., Tregnago, D., Trestini, I., Insolda, J., Bonato, A., Ugel, S., et al. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2372327 · Cited by 7
Self-citationLi, M., Lin, C., Lin, J., Chen, S., Weng, L., & He, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14637 · Cited by 6
The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors
Chen, M., Jiang, J. H., Chen, J., Wang, M., Lu, Y., Liu, L., Zhao, L., & Wang, L. (2023) · Current Drug Targets · doi:10.2174/1389450124666230330101651 · Cited by 6
Li, Y., Jiang, H., Qian, F., Chen, Y., Zhou, W., Zhang, Y., Lü, J., Lou, Y., Han, B., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161718 · Cited by 6
Self-citationMcMahon, D. J., McLaughlin, R. A., & Naidoo, J. (2024) · Cancers · doi:10.3390/cancers16030527 · Cited by 7
CT, MRI, and F-18 FDG PET for the detection of non-small-cell lung cancer (NSCLC)
Zhang, Y., Ni, J., Wei, K., Tian, J., & Sun, S. (2018) · Medicine · doi:10.1097/md.0000000000012387 · Cited by 7
Wang, S., Shi, Y., & Han, X. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.44 · Cited by 6
He, H., Yang, W., Huang, Y., Zhang, X., Peng, Y., & Yang, Z. (2021) · Angiogenesis · doi:10.1007/s10456-021-09811-8 · Cited by 6
Self-citationZhu, Y., Zhang, Y., Hu, X., Wang, M., Wang, H., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04177-w · Cited by 6
Malesa, A., Nowak, J., Skórka, K., Karp, M., & Giannopoulos, K. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0025 · Cited by 7
Prelaj, A., Russo, G. L., Proto, C., Signorelli, D., Ferrara, R., Galli, G., Toma, A. D., Randon, G., Pagani, F., Trevisan, B., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.005 · Cited by 6
Self-citationPeng, J., Zhao, X., Zhao, K., & Meng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731429 · Cited by 6
Blind Identification Of Non-Minimum Phase Systems Using The Mean Differential Cepstrum
Amont, J., Danière, J., & Guilleî, F. (2015) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.37458 · Cited by 6
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Tian, J., Shi, Z., Zhao, L., Liu, P., Sun, X., Long, L., Zang, J., & Xiao, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70037 · Cited by 5
Site-Selective Anti-PD-L1 Antibody–MMAE Conjugate for Enhanced NSCLC Therapy
Kwon, S. J., Son, J., & Chung, S. J. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00178 · Cited by 5
Huang, S., Jordan, A. I., Jenneman, D., Shafique, M. R., & Holmstrom, B. (2022) · Cureus · doi:10.7759/cureus.22295 · Cited by 5
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era
Catania, C., Piperno, G., Russo, A., Greco, C., Agustoni, F., Scotti, V., Proto, C., Sangalli, C., Patani, F., Santacaterina, A., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103684 · Cited by 6
Garon, E. B., Spira, A. I., Goldberg, S. B., Chaft, J. E., Papadimitrakopoulou, V. A., Cascone, T., Antonia, S. J., Brahmer, J. R., Camidge, D. R., Powderly, J. D., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.04.020 · Cited by 5
Self-citationWei, K., Zhou, C., Chen, Y., Feng, X., & Tang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1217872 · Cited by 5
Self-citation
Metadata
- Authors
- Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R. A., Huang, Y., Wadsworth, C., Dennis, P. A., Rizvi, N. A., Paz-Ares Rodriguez, L., Novello, S., Hiret, S., Schmid, P., Laack, E., Califano, R., Maemondo, M., Kim, S.-W., Chaft, J., Vicente Baz, D., Berghmans, T., Kim, D.-W., Surmont, V., Reck, M., Han, J.-Y., Holgado Martin, E., Belda Iniesta, C., Oe, Y., Chella, A., Chopra, A., Robinet, G., Soto Parra, H., Thomas, M., Cheema, P., Katakami, N., Su, W.-C., Kim, Y.-C., Wolf, J., Lee, J.-S., Saka, H., Milella, M., Ramos Garcia, I., Sibille, A., Yokoi, T., Kang, E. J., Atagi, S., Spaeth-Schwalbe, E., Nishio, M., Imamura, F., Gabrail, N., Veillon, R., Derijcke, S., Maeda, T., Zylla, D., Kubiak, K., Santoro, A., Uy, M. N., Lucien Geater, S., Italiano, A., Kowalski, D., Barlesi, F., Chen, Y.-M., Spigel, D., Chewaskulyong, B., Garcia Gomez, R., Alvarez Alvarez, R., Yang, C.-H., Hsia, T.-C., Denis, F., Sakai, H., Vincent, M., Goto, K., Bosch-Barrera, J., Weiss, G., Canon, J.-L., Scholz, C., Aglietta, M., Kemmotsu, H., Azuma, K., Bradbury, P., Feld, R., Chachoua, A., Jassem, J., Juergens, R., Palmero Sanchez, R., Malcolm, A., Vrindavanam, N., Kubota, K., Waller, C., Waterhouse, D., Coudert, B., Mark, Z., Satouchi, M., Chang, G.-C., Herzmann, C., Chaudhry, A., Giridharan, S., Hesketh, P., Ikeda, N., Boccia, R., Iannotti, N., Haigentz, M., Reynolds, J., Querol, J., Nakagawa, K., Sugawara, S., Tan, E. H., Hirashima, T., Gettinger, S., Kato, T., Takeda, K., Juan Vidal, O., Mohn-Staudner, A., Panwalkar, A., Daniel, D., Kobayashi, K., Ladrera, G. E. I., Schulte, C., Sebastian, M., Cernovska, M., Coupkova, H., Havel, L., Pauk, N., Singh, J., Murakami, S., Csoszi, T., Losonczy, G., Price, A., Anderson, I., Iqbal, M., Torri, V., Juhasz, E., Khanani, S., Koubkova, L., Levy, B., Page, R., Bocskei, C., Crinò, L., Einspahr, D., Hagenstad, C., Juat, N., Overton, L., Garrison, M., & Szalai, Z.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Yonsei University (KR)
- CHA University Bundang Medical Center (KR)
- Université Toulouse III - Paul Sabatier (FR)
- KU Leuven (BE)
- Moffitt Cancer Center (US)
- Carolina BioOncology Institute (US)
- Inserm (FR)
- Azienda Ospedaliera San Gerardo (IT)
- Samsung Medical Center (KR)
- National University Cancer Institute, Singapore (SG)
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Columbia University Irving Medical Center (US)
- University of Turin (IT)
- Institut de Cancérologie de l'Ouest (FR)
- Imperial College London (GB)
- Université Libre de Bruxelles (BE)
- German Center for Lung Research (DE)
- University of Palermo (IT)
- Hospital Universitario Virgen del Rocío (ES)
- University of Ottawa (CA)
- Corresponding author
- Garassino, Marina Chiara
- ORCID
- Garassino, Marina Chiara
- Cho, Byoung-Chul
- Kim, Joo-Hang
- Mazières, Julien
- Vansteenkiste, Johan
- Powderly, John
- Chouaid, Christos
- Park, Keunchil
- Soo, Ross A
- Huang, Yifan
- Rizvi, Naiyer A
- Novello, Silvia
- Hiret, Sandrine
- Schmid, Peter
- Califano, Raffaele
- Maemondo, Makoto
- Kim, Sang-We
- Chaft, Jamie
- Berghmans, Thierry
- Kim, Dong-Wan
- Surmont, Veerle
- Reck, Martin
- Han, Ji-Youn
- Chella, Antonio
- Chopra, Akhil
- Cheema, Parneet
- Katakami, Nobuyuki
- Su, Wu-Chou
- Kim, Young-Chul
- Lee, Jong-Seok
- Saka, Hideo
- Milella, Michele
- Sibille, Anne
- Yokoi, Takashi
- Kang, Eun Joo
- Atagi, Shinji
- Nishio, Makoto
- Imamura, Fumio
- Gabrail, Nashat
- Derijcke, Sofie
- Zylla, Dylan
- Santoro, Armando
- Kowalski, Dariusz
- Chen, Yuh-Min
- Spigel, David
- Hsia, Te-Chun
- Denis, Fabrice
- Sakai, Hiroshi
- Vincent, Mark
- Weiss, Glen
- Canon, Jean-Luc
- Aglietta, Massimo
- Azuma, Koichi
- Chachoua, Abraham
- Jassem, Jacek
- Juergens, Rosalyn
- Kubota, Kaoru
- Waller, Cornelius
- Waterhouse, David
- Coudert, Bruno
- Satouchi, Miyako
- Chang, Gee-Chen
- Herzmann, Christian
- Giridharan, Selvaraj
- Hesketh, Paul
- Ikeda, Norihiko
- Haigentz, Missak
- Nakagawa, Kazuhiko
- Sugawara, Shunichi
- Gettinger, Scott
- Kato, Terufumi
- Daniel, Davey
- Kobayashi, Kunihiko
- Sebastian, Martin
- Havel, Libor
- Singh, Joginder
- Murakami, Shuji
- Levy, Benjamin
- Page, Ray
- Crinò, Lucio
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 19
- Issue
- 4
- Pages
- 521-536
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7771363
- OpenAlex
- W2791290180
- Cited by
- 568
- References
- 29
- Citations by year
- 2026: 15 · 2025: 30 · 2024: 55 · 2023: 61 · 2022: 85 · 2021: 96 · 2020: 92 · 2019: 85 · 2018: 47
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- durvalumab, advanced non-small cell lung cancer, third-line therapy, PD-L1 expression, immune checkpoint inhibitors, EGFR mutation, ALK rearrangement, objective response rate, treatment safety, PD-L1 inhibitors, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Injection Site Reaction, Anaplastic Lymphoma Kinase, Progression-Free Survival, Aged, Antibodies, Monoclonal, Aspartate Aminotransferases, Carcinoma, Non-Small-Cell Lung, Diarrhea, Fatigue, Female, gamma-Glutamyltransferase, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pneumonia, 4-Butyrolactone, B7-H1 Antigen, Response Evaluation Criteria in Solid Tumors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
